Novartis Pharmaceuticals

This study looks at how well the drug asciminib works and how safe it is for young adults with chronic myeloid leukemia (CML) in the Gulf region. Researchers will collect information from medical records of about 80 people aged 18 and older who have taken asciminib. The main goal…

This phase 2 trial is testing whether an investigational drug called arumakimig can improve symptoms of VEXAS syndrome, a rare genetic autoinflammatory condition. The study will compare arumakimig against a placebo in about 120 adults with VEXAS, with the goal of seeing if the dr…

This phase 3 trial is testing an investigational drug called abelacimab in about 2,500 people with atrial fibrillation (an irregular heartbeat) who are at high risk for stroke but cannot take standard oral blood thinners. Participants will receive either abelacimab or a placebo, …

This phase 2 trial is testing whether an experimental drug called DDY391 can reduce disease activity and improve symptoms like dryness, pain, and fatigue in people with Sjögren's disease. About 344 participants will receive either DDY391 at one of three dose levels or a placebo f…

This study looks back at medical records of children with spinal muscular atrophy (SMA) type 1 who received a one-time gene therapy called onasemnogene abeparvovec (Zolgensma). Researchers want to see if treated infants can sit independently for 30 seconds or more within a year. …

This study tracks the safety of secukinumab, a biologic injection, in Indian adults with axial spondyloarthritis — a group of inflammatory conditions that cause back pain and stiffness. Over 16 weeks, researchers will monitor side effects and disease activity in about 60 particip…

This study looks at how effective the drug Pluvicto (177Lu-PSMA-617) is in treating men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. Researchers will analyze medical records from over 1,000 patients …

This study will look at how well a drug called ARNi (sacubitril/valsartan) lowers blood pressure in 500 adults with hypertension in the United Arab Emirates. Researchers will compare it to standard treatments like ACE inhibitors and calcium channel blockers. The goal is to see if…

This study tests a specially formulated dispersible tablet, Coartem Baby, in infants weighing between 2 and 5 kg who have uncomplicated malaria. The goal is to see if the drug is safe and effectively clears symptoms like fever and chills. Twenty infants will receive the standard …

This study looks back at the experiences of 35 adults with a rare kidney disease called C3G who received the drug iptacopan through a special early access program in Spain. Researchers will collect information on patient health, lab results, and how the disease responds to treatm…

This study looks at whether starting secukinumab early in people with moderate-to-severe hidradenitis suppurativa (a chronic skin condition causing painful lumps) can slow disease progression. Researchers will analyze data from existing medical records and registries across Europ…

This study tests whether adding a drug called inclisiran to standard cholesterol-lowering therapy (statins) helps people who recently had a heart attack or unstable angina lower their LDL ('bad') cholesterol more than statins alone. About 300 adults in Saudi Arabia will receive e…

This study provides continued access to alpelisib for people who are already benefiting from it in a previous Novartis trial. It focuses on tracking long-term safety, including any side effects, in participants with PIK3CA-related overgrowth spectrum or certain breast cancers. Pa…

This phase 2 trial tests whether adding ianalumab to eltrombopag helps children aged 5 to 17 with primary immune thrombocytopenia (ITP) who didn't improve after steroids. The goal is to see if the combination can raise platelet counts and prevent bleeding. About 36 children will …

This study tests a drug called pelacarsen in people who recently had a heart attack and have high levels of Lp(a), a type of fat in the blood that raises heart risk. The goal is to see if the drug can safely lower Lp(a) levels and improve heart health. About 240 adults in the US …

This study will follow 36 people with spinal muscular atrophy (SMA) who receive a gene therapy called onasemnogene abeparvovec (ITVISMA) injected into the spinal fluid. The goal is to see how well it works and how safe it is in everyday medical practice. Participants must be at l…

This phase 3 trial tests whether remibrutinib, an oral drug, can reduce severe itching in adults who have had chronic itch for at least 4 months with no known cause. Participants receive either remibrutinib or a placebo for 52 weeks. The main goal is to see if more people on the …

This study will review medical records of 400 adults in Kuwait with chronic myeloid leukemia (CML) who have received at least one type of targeted therapy (TKI). Researchers want to understand patient backgrounds, other health conditions, and how treatments are used in everyday p…

This study follows 34 adults with moderate-to-severe hidradenitis suppurativa (HS) who are taking secukinumab as part of their routine care. Researchers will use a special CT scan to check if the drug affects the buildup of plaque in the heart arteries over 12 months. The goal is…

This study will look at medical records from 3,600 people in Japan to see how well they follow their prescribed cholesterol-lowering medication. It compares two drugs, inclisiran and evolocumab, over 12 months. The goal is to understand real-world adherence, not to test new treat…

This study will observe how the drug lutetium-177 vipivotide tetraxetan is actually used in patients with metastatic prostate cancer. Researchers will collect data from medical records across multiple countries, using AI to analyze treatment patterns and outcomes. The goal is to …

This study will observe 80 adults with IgA nephropathy who are prescribed iptacopan or atrasentan as part of their routine care. Researchers will collect data on patient profiles, treatment patterns, and clinical outcomes over 24 months. The goal is to understand how these drugs …

This study looks back at medical records of about 83 adults with C3 glomerulopathy (C3G), a rare kidney disease, who are taking the drug iptacopan. Researchers will describe patients' health history, lab results, and how their disease changes over a year of treatment. The goal is…

This study follows 100 children aged 6 to 17 with juvenile psoriatic or enthesitis-related arthritis who are taking secukinumab. Researchers will observe how doctors adjust treatment after the disease becomes inactive, and whether patients experience flares. The goal is to learn …